TY - JOUR
T1 - Treatment of Advanced Pancreatic Cancer
AU - Ducreux, Michel
AU - Boige, Valérie
AU - Malka, David
PY - 2007/4
Y1 - 2007/4
N2 - Chemotherapy for the treatment of pancreatic carcinoma is clearly evolving. Recent studies have provided the first evidence in more than a decade that combining gemcitabine with another systemic agent can improve outcome over that achieved with standard gemcitabine monotherapy in patients with advanced disease. Particularly promising are the gemcitabine/capecitabine (Gem-Cap) combination, which showed a significant survival benefit over single-agent gemcitabine in a large phase III study; gemcitabine/oxaliplatin combinations, some of which use a modulated gemcitabine infusion schedule; and gemcitabine-based combinations with targeted therapies, based on a significant survival benefit achieved with gemcitabine plus the epidermal growth factor receptor inhibitor erlotinib in the phase III setting, as well as encouraging phase II results with cetuximab and bevacizumab. Further advances will probably be made with combinations of targeted therapies. Better understanding of the carcinogenesis of this very aggressive cancer is also needed.
AB - Chemotherapy for the treatment of pancreatic carcinoma is clearly evolving. Recent studies have provided the first evidence in more than a decade that combining gemcitabine with another systemic agent can improve outcome over that achieved with standard gemcitabine monotherapy in patients with advanced disease. Particularly promising are the gemcitabine/capecitabine (Gem-Cap) combination, which showed a significant survival benefit over single-agent gemcitabine in a large phase III study; gemcitabine/oxaliplatin combinations, some of which use a modulated gemcitabine infusion schedule; and gemcitabine-based combinations with targeted therapies, based on a significant survival benefit achieved with gemcitabine plus the epidermal growth factor receptor inhibitor erlotinib in the phase III setting, as well as encouraging phase II results with cetuximab and bevacizumab. Further advances will probably be made with combinations of targeted therapies. Better understanding of the carcinogenesis of this very aggressive cancer is also needed.
UR - http://www.scopus.com/inward/record.url?scp=34247164630&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2007.01.006
DO - 10.1053/j.seminoncol.2007.01.006
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17449349
AN - SCOPUS:34247164630
SN - 0093-7754
VL - 34
SP - S25-S30
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - SUPPL. 1
ER -